More than half of midlands-based cancer patients whose genomes were successfully sequenced through the 100,000 Genomes ...

Concurrent DNA and RNA sequencing revealed 15.3% more patients with actionable variants than DNA sequencing alone.

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically ...

MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from ...

Researchers analyzed whole-genome sequencing data from 76,805 patients to identify variants in 4 genes that are associated ...

More than half of midlands-based cancer patients whose genomes were successfully sequenced through the 100,000 Genomes Project.

With whole-genome sequencing and computational tools, the researchers identified genetic mutations and structural variations ...

CODA, the first ever 3D genome profiling technique, was able to make a 3D print of pre-cancerous cells found in a human ...

More than half of midlands-based cancer patients whose genomes were successfully sequenced through the 100,000 Genomes ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

In recent years, scientists have created a range of new methods based on CRISPR-Cas technology for precisely editing the ...

The gut microbiome's impact on pancreatic cancer highlights potential for early screening and fecal microbiota ...